Research view
Switch to patient viewColorectal cancer: trials that stopped early
Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Reason given in the registry “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.
- Ended
- Feb 2024
- Phase
- Phase 1/2
- Run by
- Numab Therapeutics AG
- Registry record
- NCT04442126
Withdrawn
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
Reason given in the registry “Due to errors in the previously submitted modification, we request to withdraw it and will submit a corrected update shortly.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 May 2025.
- Ended
- Dec 2025
- Phase
- Phase 2
- Run by
- Sun Yat-sen University
- Registry record
- NCT06895577
Terminated
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Reason given in the registry “Adjustment of the Company's R\&D Strategy”
Quoted unchanged from ClinicalTrials.gov; record updated 18 May 2025.
- Ended
- Apr 2024
- Phase
- Phase 2/3
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Registry record
- NCT04856787
Terminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Reason given in the registry “Study terminated by sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- Hutchmed
- Registry record
- NCT04579757
Terminated
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Reason given in the registry “PI Determination - Slow recruitment, funding concerns, poor response to treatment”
Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2025.
- Ended
- May 2024
- Phase
- Phase 2
- Run by
- University of Utah
- Registry record
- NCT04853043
Terminated
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Reason given in the registry “Funding terminated due to business reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Apr 2025.
- Ended
- Mar 2025
- Phase
- Phase 1
- Run by
- MapKure, LLC
- Registry record
- NCT06194877
Terminated
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Reason given in the registry “Lack of Efficacy”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT03610490
Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Reason given in the registry “study terminated due to changes in the drug development plan”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2025.
- Ended
- Aug 2025
- Phase
- Phase 1
- Run by
- Orion Biotechnology Polska Sp. z o.o.
- Registry record
- NCT05940844
Terminated
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Reason given in the registry “Formulation challenges”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2025.
- Ended
- Mar 2025
- Phase
- Phase 1
- Run by
- Mirati Therapeutics Inc.
- Registry record
- NCT05737706
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Apr 2025.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- Elevation Oncology
- Registry record
- NCT04383210
Suspended
Clinical Validation of Multimodal Digestive Endoscopy
Reason given in the registry “At present, this exploratory study has preliminarily achieved the set goals, and the subsequent data analysis is currently underway to determine whether it is necessary to continue recruiting participants.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2025.
- Ended
- Apr 2025
- Run by
- Xijing Hospital of Digestive Diseases
- Registry record
- NCT05575765
Terminated
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
Reason given in the registry “Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient management in the majority of centers, the IDMC experts recommended halting inclusion in the SOREGATT study with immediate effect.”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2025.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- UNICANCER
- Registry record
- NCT04450836
Terminated
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
Reason given in the registry “DSMC-directed closure”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Mar 2025.
- Ended
- Nov 2023
- Phase
- Phase 1
- Run by
- University of Iowa
- Registry record
- NCT04108481
Suspended
Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
Reason given in the registry “Pilot study findings pointed to a overhaul in study design”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Mar 2025.
- Phase
- Phase 2
- Run by
- UMC Utrecht
- Registry record
- NCT05375708
Terminated
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
Reason given in the registry “The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not support the trial's purpose.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Mar 2025.
- Ended
- Jan 2025
- Phase
- Phase 2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04952753
Withdrawn
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Reason given in the registry “The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Mar 2025.
- Ended
- Aug 2025
- Run by
- Pfizer
- Registry record
- NCT04889495
Terminated
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Reason given in the registry “Not meeting recruitment timelines”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Mar 2025.
- Ended
- Feb 2025
- Phase
- Phase 3
- Run by
- Peter MacCallum Cancer Centre, Australia
- Registry record
- NCT04316013
Terminated
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
Reason given in the registry “Company decision”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Mar 2025.
- Ended
- Nov 2023
- Phase
- Phase 1
- Run by
- Boehringer Ingelheim
- Registry record
- NCT05446129
Withdrawn
UNTIRE: Cancer-related Fatigue With Digital Treatment
Reason given in the registry “loss of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2025.
- Ended
- Jan 2026
- Run by
- Dana-Farber Cancer Institute
- Registry record
- NCT05584540
Terminated
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2025.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- Turnstone Biologics, Corp.
- Registry record
- NCT05576077
Terminated
Study of rSIFN-co for Patients With Advanced Solid Tumors
Reason given in the registry “Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Feb 2025.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Sichuan Huiyang Life Science and Technology Corporation
- Registry record
- NCT02464007
Terminated
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
Reason given in the registry “slow accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2025.
- Ended
- Oct 2024
- Phase
- Early phase 1
- Run by
- Mayo Clinic
- Registry record
- NCT04213794
Terminated
TATE and KN046 in MCRC
Reason given in the registry “Business Operation Strategy Adjustment”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Feb 2025.
- Ended
- Jan 2025
- Phase
- Phase 2
- Run by
- Zhejiang Raygene Pharmaceuticals Co., Ltd
- Registry record
- NCT06834399
Terminated
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Reason given in the registry “This was a strategic business decision. There were no safety concerns contributing to this decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Feb 2025.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Incyte Corporation
- Registry record
- NCT05909995
Terminated
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Reason given in the registry “Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- Biomea Fusion Inc.
- Registry record
- NCT05631574
Terminated
A Study of SGN-STNV in Advanced Solid Tumors
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Seagen Inc.
- Registry record
- NCT04665921
Terminated
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
Reason given in the registry “enrollment too slow”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Centre Hospitalier Universitaire de Besancon
- Registry record
- NCT03117972
Withdrawn
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
Reason given in the registry “Per drug sponsor request.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Feb 2025.
- Phase
- Phase 2
- Run by
- Ibrahim Halil Sahin
- Registry record
- NCT06365970
Withdrawn
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
Reason given in the registry “Study was not able to enroll any subjects”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2025.
- Ended
- Jan 2026
- Phase
- Phase 1/2
- Run by
- University of Alabama at Birmingham
- Registry record
- NCT03764137
Terminated
A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients
Reason given in the registry “lack of enrolment”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Jan 2025.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- Ente Ospedaliero Ospedali Galliera
- Registry record
- NCT03047837
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.